Antiviral evaluation of 1,4-disubstituted-1,2,3-triazole derivatives against Chikungunya virus

Papers of special note have been highlighted as: • of interest; •• of considerable interest

References

• 1. Kril V, Aiqui-Reboul-Paviet O, Briant L, Amara A. New insights into chikungunya virus infection and pathogenesis. Annu. Rev. Virol. 8(1), 327–347 (2021).
  MedlineGoogle Scholar
• 2. Weaver SC. Arrival of chikungunya virus in the new world: prospects for spread and impact on public health. PLOS Negl. Trop. Dis. 8(6), e2921 (2014).
  MedlineGoogle Scholar
• 3. Puntasecca CJ, King CH, Labeaud AD. Measuring the global burden of chikungunya and Zika viruses: a systematic review. PLOS Negl. Trop. Dis. 15(3), e0009055 (2021).
  MedlineGoogle Scholar
• 4. Sharif N, Sarkar MK, Ferdous RN et al. Molecular epidemiology, evolution and reemergence of chikungunya virus in South Asia. Front. Microbiol. 12, (2021).
  Google Scholar
• 5. Manzoor KN, Javed F, Ejaz M et al. The global emergence of chikungunya infection: an integrated view. Rev. Med. Virol. 32(3), e2287 (2022).
  Medline CASGoogle Scholar
• 6. Wimalasiri-Yapa BMCR, Stassen L, Huang X et al. Chikungunya virus in Asia - Pacific: a systematic review. Emerg. Microbes Infect. 8(1), 70–79 (2019).
  MedlineGoogle Scholar
• 7. de Lima Cavalcanti TYV, Pereira MR, Paula SO, Franca RFO. A review on chikungunya virus epidemiology, pathogenesis and current vaccine development. Viruses 14(5), 969 (2022).
  MedlineGoogle Scholar
• 8. Chala B, Hamde F. Emerging and re-emerging vector-borne infectious diseases and the challenges for control: a review. Front. Public Heal. 9, (2021).
  Google Scholar
• 9. ECDC. Chikungunya worldwide overview (2023). www.ecdc.europa.eu/en/chikungunya-monthly
  Google Scholar
• 10. Paixão ES, Rodrigues LC, Costa MDCN et al. Chikungunya chronic disease: a systematic review and meta-analysis. Trans. R. Soc. Trop. Med. Hyg. 112(7), 301–316 (2018).
  MedlineGoogle Scholar
• 11. Ganesan V, Duan B, Reid S. Chikungunya virus: pathophysiology, mechanism, and modeling. Viruses 9(12), 1–14 (2017).
  Google Scholar
• 12. van Ewijk R, Huibers MHW, Manshande ME et al. Neurologic sequelae of severe chikungunya infection in the first 6 months of life: a prospective cohort study 24-months post-infection. BMC Infect. Dis. 21(1), 179 (2021).
  MedlineGoogle Scholar
• 13. Gao S, Song S, Zhang L. Recent progress in vaccine development against chikungunya virus. Front. Microbiol. 10, 1–10 (2019).
  MedlineGoogle Scholar
• 14. Schneider M, Narciso-Abraham M, Hadl S et al. Safety and immunogenicity of a single-shot live-attenuated chikungunya vaccine: a double-blind, multicentre, randomised, placebo-controlled, phase 3 trial. Lancet 401(10394), 2138–2147 (2023).
  Medline CASGoogle Scholar
• 15. Battisti V, Urban E, Langer T. Antivirals against the Chikungunya Virus. Viruses 13(7), 1307 (2021). •• This study reinforce that the search for novel specific antivirals against CHIKV is highly needed.
  Medline CASGoogle Scholar
• 16. Bozorov K, Zhao J, Aisa HA. 1,2,3-Triazole-containing hybrids as leads in medicinal chemistry: a recent overview. Bioorg. Med. Chem. 27(16), 3511–3531 (2019).
  Medline CASGoogle Scholar
• 17. Bonandi E, Christodoulou MS, Fumagalli G, Perdicchia D, Rastelli G, Passarella D. The 1,2,3-triazole ring as a bioisostere in medicinal chemistry. Drug Discov. Today 22(10), 1572–1581 (2017).
  Medline CASGoogle Scholar
• 18. Kharb R, Yar MS, Sharma PC. Recent advances and future perspectives of triazole analogs as promising antiviral agents. Mini-Reviews Med. Chem. 11(1), 84–96 (2011).
  Medline CASGoogle Scholar
• 19. da S M Forezi L, Lima CGS, Amaral AAP et al. Bioactive 1,2,3-triazoles: an account on their synthesis, structural diversity and biological applications. Chem. Rec. 21(10), 2782–2807 (2021).
  MedlineGoogle Scholar
• 20. da Silva VD, de Faria BM, Colombo E et al. Design, synthesis, structural characterization and in vitro evaluation of new 1,4-disubstituted-1,2,3-triazole derivatives against glioblastoma cells. Bioorg. Chem. 83, 87–97 (2019). •• This is the first report of the studied triazole derivatives.
  Medline CASGoogle Scholar
• 21. Almeida-Souza F, da Silva VD, Silva GX et al. 1,4-disubstituted-1,2,3-triazole compounds induce ultrastructural alterations in Leishmania amazonensis promastigote: an in vitro antileishmanial and in silico pharmacokinetic study. Int. J. Mol. Sci. 21(18), 1–20 (2020).
  Google Scholar
• 22. Viegas DJ, da Silva VD, Buarque CD, Bloom DC, Abreu PA. Antiviral activity of 1,4-disubstituted-1,2,3-triazoles against HSV-1 in vitro. Antivir. Ther. 25(8), 399–410 (2020). •• Our group uncovered the antiviral activity of the studied compounds against Herpes simplex virus type 1.
  Medline CASGoogle Scholar
• 23. Cirne-Santos CC, Barros CS, Nogueira CCR et al. Inhibition by marine algae of chikungunya virus isolated from patients in a recent disease outbreak in rio de janeiro. Front. Microbiol. 10, 1–11 (2019).
  MedlineGoogle Scholar
• 24. Khan M, Santhosh SR, Tiwari M, Lakshmana Rao PV, Parida M. Assessment of in vitro prophylactic and therapeutic efficacy of chloroquine against chikungunya virus in vero cells. J. Med. Virol. 82(5), 817–824 (2010).
  Medline CASGoogle Scholar
• 25. Fox JM, Long F, Edeling MA et al. Broadly neutralizing alphavirus antibodies bind an epitope on E2 and inhibit entry and egress. Cell 163(5), 1095–1107 (2015).
  Medline CASGoogle Scholar
• 26. Lani R, Hassandarvish P, Shu MH et al. Antiviral activity of selected flavonoids against Chikungunya virus. Antiviral Res. 133, 50–61 (2016).
  Medline CASGoogle Scholar
• 27. O'Boyle NM, Banck M, James CA, Morley C, Vandermeersch T, Hutchison GR. Open Babel: an open chemical toolbox. J. Cheminform. 3(1), 33 (2011).
  MedlineGoogle Scholar
• 28. Rabelo VWH, de Palmer Paixão ICN, Abreu PA. Structural insights into the inhibition of the nsP2 protease from Chikungunya virus by molecular modeling approaches. J. Mol. Model. 28(10), 311 (2022). • Computational tools can support the development of novel anti-CHIKV compounds and aid the investigation of their mechanism of action.
  Medline CASGoogle Scholar
• 29. Jones R, Bragagnolo G, Arranz R, Reguera J. Capping pores of alphavirus nsP1 gate membranous viral replication factories. Nature 589(7843), 615–619 (2021).
  Medline CASGoogle Scholar
• 30. Zhang K, Law YS, Law MCY, Tan YB, Wirawan M, Luo D. Structural insights into viral RNA capping and plasma membrane targeting by Chikungunya virus nonstructural protein 1. Cell Host Microbe 29(5), 757–764.e3 (2021).
  Medline CASGoogle Scholar
• 31. Fatma B, Kumar R, Singh VA et al. Alphavirus capsid protease inhibitors as potential antiviral agents for Chikungunya infection. Antiviral Res. 179, DOI: 10.1016/j.antiviral.2020.104808 (2020).
  MedlineGoogle Scholar
• 32. Delang L, Li C, Tas A et al. The viral capping enzyme nsP1: a novel target for the inhibition of chikungunya virus infection. Sci. Rep. 6(1), 1–10 (2016).
  MedlineGoogle Scholar
• 33. Ivanova L, Rausalu K, Žusinaite E, Tammiku-Taul J, Merits A, Karelson M. 1,3-thiazolbenzamide derivatives as chikungunya virus nsP2 protease inhibitors. ACS Omega 6(8), 5786–5794 (2021).
  Medline CASGoogle Scholar
• 34. Ferraz AC, Moraes TFS, Nizer WSDC et al. Virucidal activity of proanthocyanidin against Mayaro virus. Antiviral Res. 168, 76–81 (2019).
  Medline CASGoogle Scholar
• 35. Roques P, Thiberville SD, Dupuis-Maguiraga L et al. Paradoxical effect of chloroquine treatment in enhancing chikungunya virus infection. Viruses. 10(5), 268 (2018). • This study reported that chloroquine fails to combat CHIKV infection in humans and non-human primates.
  MedlineGoogle Scholar
• 36. De Lamballerie X, Boisson V, Reynier JC et al. On chikungunya acute infection and chloroquine treatment. Vector-Borne Zoonotic Dis. 8(6), 837–839 (2008).
  MedlineGoogle Scholar
• 37. Cirne-Santos CC, de Souza Barros C, de Oliveira MC et al. In vitro studies on the inhibition of replication of Zika and chikungunya viruses by dolastane isolated from seaweed Canistrocarpus cervicornis. Sci. Rep. 10(1), 1–10 (2020).
  MedlineGoogle Scholar
• 38. Franco EJ, Rodriquez JL, Pomeroy JJ, Hanrahan KC, Brown AN. The effectiveness of antiviral agents with broad-spectrum activity against chikungunya virus varies between host cell lines. Antivir. Chem. Chemother. 26, (2018).
  MedlineGoogle Scholar
• 39. Rothan HA, Bahrani H, Mohamed Z et al. A combination of doxycycline and ribavirin alleviated chikungunya infection. PLOS ONE 10(5), 1–15 (2015).
  Google Scholar
• 40. Ravichandran R, Manian M. Ribavirin therapy for chikungunya arthritis. J. Infect. Dev. Ctries. 2(2), 140–142 (2008).
  Medline CASGoogle Scholar
• 41. Sinclair SM, Jones JK, Miller RK, Greene MF, Kwo PY, Maddrey WC. The ribavirin pregnancy registry: an interim analysis of potential teratogenicity at the mid-point of enrollment. Drug Saf. 40(12), 1205–1218 (2017). • This study report that the clinical use of ribavirin has some limitations, which supports the search for novel alternatives to treat CHIKV infections.
  Medline CASGoogle Scholar
• 42. Gigante A, Canela MD, Delang L et al. Identification of [1,2,3]triazolo[4,5-d]pyrimidin-7(6H)-ones as novel inhibitors of chikungunya virus replication. J. Med. Chem. 57(10), 4000–4008 (2014).
  Medline CASGoogle Scholar
• 43. Gigante A, Gómez-SanJuan A, Delang L et al. Antiviral activity of [1,2,3]triazolo[4,5-d]pyrimidin-7(6H)-ones against chikungunya virus targeting the viral capping nsP1. Antiviral Res. 144, 216–222 (2017).
  Medline CASGoogle Scholar
• 44. Gómez-Sanjuan A, Gamo AM, Delang L et al. Inhibition of the replication of different strains of chikungunya virus by 3-Aryl-[1,2,3]triazolo[4,5-d] pyrimidin-7(6 H)-ones. ACS Infect. Dis. 4(4), 605–619 (2018). • This study reports a triazole derivative with antiviral potential against the replication of different CHIKV strains in Vero cells.
  Medline CASGoogle Scholar
• 45. Cassell S, Edwards J, Brown DT. Effects of lysosomotropic weak bases on infection of BHK-21 cells by Sindbis virus. J. Virol. 52(3), 857–864 (1984).
  Medline CASGoogle Scholar
• 46. Delogu I, Pastorino B, Baronti C, Nougairède A, Bonnet E, de Lamballerie X. In vitro antiviral activity of arbidol against Chikungunya virus and characteristics of a selected resistant mutant. Antiviral Res. 90(3), 99–107 (2011).
  Medline CASGoogle Scholar
• 47. Oo A, Rausalu K, Merits A et al. Deciphering the potential of baicalin as an antiviral agent for Chikungunya virus infection. Antiviral Res. 150, 101–111 (2018).
  Medline CASGoogle Scholar
• 48. Ho YJ, Wang YM, Lu JW et al. Suramin inhibits chikungunya virus entry and transmission. PLOS ONE 10(7), 1–18 (2015).
  CASGoogle Scholar
• 49. Delang L, Guerrero NS, Tas A et al. Mutations in the chikungunya virus non-structural proteins cause resistance to favipiravir (T-705), a broad-spectrum antiviral. J. Antimicrob. Chemother. 69(10), 2770–2784 (2014).
  Medline CASGoogle Scholar
• 50. Li N, Wang Z, Wang R et al. In vitro inhibition of alphaviruses by lycorine. Virol. Sin. 36(6), 1465–1474 (2021).
  Medline CASGoogle Scholar
• 51. Wan JJ, Brown RS, Kielian M. Berberine chloride is an alphavirus inhibitor that targets nucleocapsid assembly. MBio 11(3), 1–21 (2020).
  Google Scholar
• 52. Devaux CA, Rolain JM, Colson P, Raoult D. New insights on the antiviral effects of chloroquine against coronavirus: what to expect for COVID-19? Int. J. Antimicrob. Agents 55(5), DOI: 10.1016/j.ijantimicag.2020.105938 (2020).
  Google Scholar
• 53. Galati S, Di Stefano M, Martinelli E, Poli G, Tuccinardi T. Recent advances in in silico target fishing. Molecules 26(17), 5124 (2021).
  Medline CASGoogle Scholar
• 54. Abdelnabi R, Kovacikova K, Moesslacher J et al. Novel class of chikungunya virus small molecule inhibitors that targets the viral capping machinery. Antimicrob. Agents Chemother. 64(7), e00649–20 (2020).
  Medline CASGoogle Scholar
• 55. Mudgal R, Mahajan S, Tomar S. Inhibition of Chikungunya virus by an adenosine analog targeting the SAM-dependent nsP1 methyltransferase. FEBS Lett. 594(4), 678–694 (2020).
  Medline CASGoogle Scholar
• 56. Mudgal R, Bharadwaj C, Dubey A et al. Selective estrogen receptor modulators limit alphavirus infection by targeting the viral capping enzyme nsP1. Antimicrob. Agents Chemother. 66(3), e0194321 (2022).
  MedlineGoogle Scholar
• 57. Adalja A, Inglesby T. Broad-spectrum antiviral agents: a crucial pandemic tool. Expert Rev. Anti. Infect. Ther. 17(7), 467–470 (2019).
  Medline CASGoogle Scholar
• 58. Pérez-Pérez MJ, Delang L, Ng LFP, Priego EM. Chikungunya virus drug discovery: still a long way to go? Expert Opin. Drug Discov. 14(9), 855–866 (2019).
  Medline CASGoogle Scholar